837344.BJ
Stock Code | Beijing Stock Exchange
Stock Code | Beijing Stock Exchange
Beijing Tri-Prime Gene Pharmaceutical Co, Ltd. (Abbr.: Tri-Prime Gene, stock code: 837344) with a registered capital of RMB 121.81 million, specializes in R&D, production, and commercialization of modern biopharmaceuticals, establishing itself as a leader in both fundamental research and clinical application of gene engineering drugs in China.
Learn Moreeffective invention patents
1992~2025
Supported by China’s National 863 Program and "Eleventh Five-Year" Major New Drug Development Project, this optimized biologic targets facial herpes simplex to accelerate lesion healing and reduce recurrence.
Learn More
National "11th Five-Year Plan" Major New Drug Development and Manufacturing Technology Project "Biological Large Variety Reform Project", for the treatment of common acquired blindness diseases - simplex herpes virus keratitis.
Learn More
Class I New Drug, National Key New Product, Beijing's Major Scientific and Technological Achievement Promotion Plan Project, indicated for viral infections and several malignant tumors.
Learn More
Recognized as a National Key New Product and Beijing Innovation Product, this therapeutic advances through Beijing’s Major High-Tech Industrialization Project and Zhongguancun National Innovation Zone, targeting viral infections and select malignancies.
Learn More
A novel broad-spectrum antimicrobial therapeutic product. Provides both symptomatic and causal treatment, with dual preventive-therapeutic effects, wide applicability, and convenient usage.
Learn More
Through optimization of vectors for the recombinant protein expression sγδTem in Escherichia coli, optimization of fermentation processes, and purification process improvements, we have taken the lead in China to innovatively produce a variety... ...
By establishing a high-stability water solution technology platform for recombinant proteins, we have successfully developed water injections, nebulizers, drops, pre-filled syringes, and various dosage forms of interferon subtypes including human... ...
Currently, the long-acting technology of protein drugs mainly relies on polyethylene glycol (PEG) modification and albumin fusion expression, with industrial applications already realized for imported long-acting antagonists... ...
Tri-Prime Gene will design and establish a cellular therapy engineering center integrated into the company's new factory area for intelligent production and R&D base project construction. This platform possesses natural γδT cell activation and expansion... ...
Stock Code | Beijing Stock Exchange
Address: No. 20, Jinghong Avenue, Daxing District, Beijing (Zipcode: 102600)
Phone: 0086-10-60219856
Free Hotline: 400-813-1918
Copyright 2018-2025 北京三元基因药业股份有限公司 版权所有 京ICP备17047089号-1
京公网安备11011502005363号 药品医疗器械网络信息服务备案：(京)网药械信息备字(2023)第 00466 号
Drug-related content is intended for medical and pharmaceutical professionals only
